vbl
therapeutics
announces
enrollment
first
patients
phase
clinical
trial
metastatic
colorectal
cancer
study
investigate
first
time
combination
checkpoint
inhibitor
nivolumab
tel
aviv
israel
globe
newswire
vbl
therapeutics
nasdaq
vblt
announced
today
first
two
patients
enrolled
phase
clinical
trial
combination
nivolumab
immune
checkpoint
inhibitor
treatment
metastatic
colorectal
cancer
study
conducted
cooperative
research
development
agreement
crada
national
cancer
institute
nci
vbl
colon
cancer
one
common
cancers
worldwide
approaches
gastrointestinal
cancers
unfortunately
largely
unsuccessful
said
tim
greten
deputy
branch
chief
senior
investigator
thoracic
gi
malignancies
branch
tgmb
nci
center
cancer
research
ccr
liver
cancer
program
principal
investigator
study
reasons
unclear
doubt
relate
fact
advanced
disease
gi
cancer
appears
less
immunogenic
goal
phase
study
investigate
whether
priming
followed
addition
nivolumab
may
induce
immune
response
metastatic
colorectal
cancer
remains
major
unmet
pleased
see
beginning
enrollment
study
despite
challenges
said
dror
harats
chief
executive
officer
vbl
therapeutics
look
forward
collaborating
nci
investigating
potential
benefit
patients
colorectal
additional
information
study
refer
https
show
patients
interested
enrolling
clinical
study
please
contact
nci
number
tty
web
site
https
vbl
vascular
biogenics
operating
vbl
therapeutics
clinical
stage
biopharmaceutical
company
focused
discovery
development
commercialization
treatments
areas
unmet
need
cancer
immune
inflammatory
indications
vbl
developed
three
platform
technologies
based
technology
targeting
newly
formed
blood
vessels
focus
cancer
technology
targeting
applications
lecinoxoids
family
indications
vbl
lead
oncology
product
candidate
ofranergene
obadenovec
targeted
agent
developed
treat
wide
range
solid
tumors
conveniently
administered
iv
infusion
every
weeks
observed
cancer
patients
demonstrated
activity
signals
comers
phase
trial
well
three
phase
studies
ofranergene
obadenovec
currently
studied
phase
potential
registration
trial
ovarian
cancer
forward
looking
statements
press
release
contains
statements
statements
statements
historical
fact
statements
often
indicated
terms
anticipate
believe
could
estimate
expect
goal
intend
look
forward
may
plan
potential
predict
project
would
similar
expressions
statements
include
limited
statements
regarding
programs
including
including
clinical
development
timing
clinical
trials
expected
announcement
data
therapeutic
potential
clinical
results
financial
position
cash
runway
statements
promises
guarantees
involve
substantial
risks
uncertainties
among
factors
could
cause
actual
results
differ
materially
described
projected
herein
include
uncertainties
associated
generally
research
development
clinical
trials
related
regulatory
reviews
approvals
risk
historical
clinical
trial
results
may
predictive
future
trial
results
impact
pandemic
business
operations
clinical
trials
supply
chain
strategy
goals
anticipated
timelines
clinical
results
financial
resources
last
long
anticipated
may
realize
expected
benefits
intellectual
property
protection
list
description
risks
uncertainties
risks
found
regulatory
filings
securities
exchange
commission
including
annual
report
form
year
ended
december
subsequent
filings
sec
existing
prospective
investors
cautioned
place
undue
reliance
statements
speak
date
hereof
vbl
therapeutics
undertakes
obligation
update
revise
information
contained
press
release
whether
result
new
information
future
events
circumstances
otherwise
investor
contact
michael
rice
lifesci
advisors
mrice
